DAVID J KOBULNICKY MD NPI 1245676477

NPI Details

David J Kobulnicky, MD is a hematology and oncology internal medicine in Hampton, VA with 13 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. David J Kobulnicky, MD NPI is 1245676477. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: VIRGINIA COMMONWEALTH UNIVERSITY, SCHOOL OF MEDICINE
Graduation Year:2013

The provider's business location address is:

3000 COLISEUM DR STE 104
HAMPTON, VA
ZIP 23666-963
Phone: (757) 827-9400
Fax: (757) 827-9320

The NPI 1245676477 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Flow cytometry technique for dna or cell analysis, each additional marker (HCPCS:88185)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Measurement of substance using immunoassay technique (HCPCS:83520)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Ferritin (blood protein) level (HCPCS:82728)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Injection, iron dextran, 50 mg (HCPCS:J1750)
• Protein measurement, serum (HCPCS:84165)
• Immunologic analysis technique on serum (immunofixation) (HCPCS:86334)
• Blood test, clotting time (HCPCS:85610)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mg (HCPCS:Q5120)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Magnesium level (HCPCS:83735)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Thyroxine (thyroid chemical), free (HCPCS:84439)
• Unclassified drugs (HCPCS:J3490)
• Telephone medical discussion with physician, 5-10 minutes (HCPCS:99441)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Red blood count automated, with additional calculations (HCPCS:85046)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Telephone medical discussion with physician, 11-20 minutes (HCPCS:99442)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Haptoglobin (serum protein) level (HCPCS:83010)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Phosphate level (HCPCS:84100)
• Flow cytometry technique for dna or cell analysis, first marker (HCPCS:88184)
• Urinalysis, manual test (HCPCS:81002)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Vitamin d-3 level (HCPCS:82306)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Administration of chemotherapy into vein using push technique (HCPCS:96409)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Red blood cell sedimentation rate, to detect inflammation, non-automated (HCPCS:85651)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Established patient office or other outpatient visit, 10-19 minutes (HCPCS:99212)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Telephone medical discussion with physician, 21-30 minutes (HCPCS:99443)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Beta-2 microglobulin (protein) level (HCPCS:82232)
• Folic acid level, serum (HCPCS:82746)
• Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage (HCPCS:90694)
• Administration of influenza virus vaccine (HCPCS:G0008)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• Follow-up hospital inpatient care per day, typically 15 minutes (HCPCS:99231)

The enumeration date for this NPI number is 5/15/2013 and was last updated on 1/12/2022.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: